Indiana is currently home to 1224 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Intervention to Change Affect Recognition and Empathy
Recruiting
Determine the feasibility, practicality, and early efficacy of a TeleRehab program (ICARE) to improve outcomes for persons with traumatic brain injury (TBI) in recognizing and responding to others' emotions alongside their care partner (CP).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Traumatic Brain Injury, Concussion, Intermediate, Concussion, Severe, Concussion With LOC 31 to 59 Minutes, Concussion With Brief Loss of Consciousness, Traumatic Brain Injury With Brief Loss of Consciousness, Traumatic Brain Injury With Loss of Consciousness, Traumatic Brain Injury With Prolonged Loss of Consciousness, Traumatic Brain Injury (TBI); Concussion, Initial Encounter, Traumatic Brain Injury (TBI); Concussion, Subsequent Encounter, Traumatic Brain Injury With No Loss of Consciousness, Traumatic Brain Injury With Open Intracranial Wound, Traumatic Brain Injury With Moderate Loss of Consciousness
Bevacizumab Treatment For Type 1 ROP
Recruiting
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Gender:
ALL
Ages:
6 months and below
Trial Updated:
06/09/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Retinopathy of Prematurity
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
Recruiting
A randomized trial to determine whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia in children 3 to \<13 years of age.
Gender:
ALL
Ages:
Between 3 years and 13 years
Trial Updated:
06/09/2025
Locations: Indiana School of Optometry, Bloomington, Indiana
Conditions: Amblyopia
Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression
Recruiting
The purpose of this study is to improve behavior control displayed by persons with traumatic brain injury by assessing effectiveness of treatments for post-TBI irritability and aggression.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/09/2025
Locations: Indiana University and Rehabilitation Hospital of Indiana, Indianapolis, Indiana
Conditions: Traumatic Brain Injury
Pediatric Prehospital Airway Resuscitation Trial
Recruiting
This study is a Phase 3, multi-center, Bayesian Adaptive Sequential Platform Trial testing the effectiveness of different prehospital airway management strategies in the care of critically ill children. Emergency Medical Services (EMS) agencies affiliated with the Pediatric Emergency Care Applied Research Network (PECARN) will participate in the trial. The study interventions are strategies of prehospital airway management: \[BVM-only\], \[BVM followed by SGA\] and \[BVM followed by ETI\]. The p... Read More
Gender:
ALL
Ages:
Between 24 hours and 17 years
Trial Updated:
06/08/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Heart Arrest, Out-Of-Hospital, Wounds and Injuries, Respiratory Insufficiency in Children, Child, Only, Critical Illness
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/06/2025
Locations: Associated Vitreoretinal and Uveitis Consultants LLC, Carmel, Indiana
Conditions: Wet Age-related Macular Degeneration
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
Recruiting
This purpose of this trial is to demonstrate 30 day safety and effectiveness outcomes of the KARDION CORY P4 System in subjects who require hemodynamic support during a high-risk PCI procedure.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/06/2025
Locations: Ascension St. Vincent, Indianapolis, Indiana
Conditions: Coronary Artery Disease
LGMD R1 Natural History Study
Recruiting
This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
Gender:
ALL
Ages:
Between 12 years and 50 years
Trial Updated:
06/06/2025
Locations: The Community Health Clinic, Inc., Shipshewana, Indiana
Conditions: Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
Recruiting
The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Squamous Cell Carcinoma, Nonmelanoma Skin Cancer, Cutaneous Squamous Cell Carcinoma
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Recruiting
The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tests to diagnose individuals at risk for developing difficulties with thinking and memory due to their cancer treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Parkview Cancer Institute, Fort Wayne, Indiana
Conditions: Neoplasm, Colorectal, Cognitive Impairment, Cognitive Dysfunction, Cognitive Change, Chemo-brain, Chemo Fog, Chemotherapy Effect, Cognitive Decline
Effects of Dietary Nitrate in Women With Secondary Amenorrhea
Recruiting
Excessive exercise, disordered attitudes toward eating, physical and psychological stress, and/or hormonal imbalances may result in cessation of menstruation (secondary amenorrhea). The accompanying lack of estrogen may impair muscle power and oxygen recovery after exercise by reducing nitric oxide levels. The purpose of this study is to determine whether ingestion of beetroot juice containing nitrate, an alternative source of nitric oxide, can help reverse these changes.
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
06/05/2025
Locations: Indiana University Indianapolis, Indianapolis, Indiana
Conditions: Secondary Amenorrhea
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Recruiting
The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/05/2025
Locations: Associated Vitreoretinal and Uveitis Consultants, Carmel, Indiana
Conditions: Age Related Macular Degeneration (ARMD)